PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups

Breast Cancer Research

Volumn 14, Issue 1, 2012, Pages

  Cizkova, Magdalena ^a,b   Susini, Aurélie ^a   Vacher, Sophie ^a   Cizeron Clairac, Géraldine ^a   Andrieu, Catherine ^a   Driouch, Keltouma ^a   Fourme, Emmanuelle ^a   Lidereau, Rosette ^a   Bièche, Ivan ^a  

^a INSTITUT CURIE   (France)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; LAPATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA, HUMAN; PIK3CA PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; EXON; FEMALE; FOLLOW UP; FRAMESHIFT MUTATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIMARY TUMOR; TUMOR VOLUME; ADULT; AGED; BREAST TUMOR; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; MORTALITY; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION, MISSENSE; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE;

EID: 84856767715     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3113     Document Type: Article

References (35)

1. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008, 27:5486-5496. 10.1038/onc.2008.244, 2757120, 18794883.
2. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007, 26:1338-1345. 10.1038/sj.onc.1210202, 17322919.
3. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7:561-573. 10.1016/j.ccr.2005.05.014, 15950905.
4. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006, 94:455-459. 10.1038/sj.bjc.6602970, 2361173, 16449998.
5. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 2005, 102:18443-18448. 10.1073/pnas.0508988102, 1317954, 16339315.
6. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006, 103:1475-1479. 10.1073/pnas.0510857103, 1360603, 16432179.
7. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65:2554-2559. 10.1158/0008-5472-CAN-04-3913, 15805248.
8. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091. 10.1158/0008-5472.CAN-07-6854, 2680495, 18676830.
9. Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 2010, 70:5674-5678. 10.1158/0008-5472.CAN-08-2660, 2905503, 20551053.
10. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009, 69:4116-4124. 2737191, 19435916.
11. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009, 15:5049-5059. 10.1158/1078-0432.CCR-09-0632, 19671852.
12. Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006, 96:91-95. 10.1007/s10549-005-9048-0, 16317585.
13. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007, 13:408-414. 10.1158/1078-0432.CCR-06-0267, 17202311.
14. Pérez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjöld B, Rutqvist LE, Skoog L, Stål O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007, 13:3577-3584. 10.1158/1078-0432.CCR-06-1609, 17575221.
15. Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011, 13:R21. 10.1186/bcr2833, 3219179, 21362200.
16. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007, 13:6064-6069. 10.1158/1078-0432.CCR-07-0266, 17947469.
17. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010, 177:1647-1656. 10.2353/ajpath.2010.090885, 2947262, 20813970.
18. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 2010, 107:10208-10213. 10.1073/pnas.0907011107, 2890442, 20479250.
19. Bièche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, Vidaud M. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999, 45:1148-1156.
20. Bièche I, Parfait B, Laurendeau I, Girault I, Vidaud M, Lidereau. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 2001, 20:8109-8115. 10.1038/sj.onc.1204917, 11781824.
21. Onody P, Bertrand F, Muzeau F, Bièche I, Lidereau R. Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: application to node-negative breast cancer. Arch Pathol Lab Med 2001, 125:746-750.
22. Bossard C, Bieche I, Le Doussal V, Lidereau R, Sabourin JC. Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma. Anticancer Res 2005, 25:4679-4683.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
24. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977, 35:1-39. 10.1038/bjc.1977.1, 2025310, 831755.
25. Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972, 34:187-220.
26. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004, 3:772-775. 10.4161/cbt.3.8.994, 15254419.
27. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004, 64:7678-7681. 10.1158/0008-5472.CAN-04-2933, 15520168.
28. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480. 10.1038/sj.onc.1208304, 15608678.
29. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009, 15:2472-2478. 10.1158/1078-0432.CCR-08-1763, 19276248.
30. Michelucci A, Di Cristofano C, Lami A, Collecchi P, Caligo A, Decarli N, Leopizzi M, Aretini P, Bertacca G, Porta RP, Ricci S, Della Rocca C, Stanta G, Bevilacqua G, Cavazzana A. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol 2009, 18:200-205. 10.1097/PDM.0b013e31818e5fa4, 19861897.
31. Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D, Marchetti A. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 2006, 208:350-355. 10.1002/path.1908, 16353168.
32. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402. 10.1016/j.ccr.2007.08.030, 17936563.
33. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008, 68:9221-9230. 10.1158/0008-5472.CAN-08-1740, 2587064, 19010894.
34. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C, Maira SM. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 2009, 106:22299-22304. 10.1073/pnas.0905152106, 2799764, 20007781.
35. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, Guan J, Berry L, Prior WW, Amler LC, Belvin M, Friedman LS, Lackner MR. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010, 16:3670-3683. 10.1158/1078-0432.CCR-09-2828, 20453058.